(Date:11/21/2008)...nted to get cosmetic surgery but either couldn,t a...rocedure? A new facelift takes the fear out of cos...xtremely safe, minimally invasive, convenient and ...sults. What more could you ask for? , ... 2008 -- Soluna MD, also known as Soluna Aesthetic...
(Date:11/21/2008)...my Rees Anderson, was invited to participate with ...2008 National Summit on Personalized Health Care. ...November 20, 2008 -- MediConnect CEO, Amy Rees And...ary of Health, Michael Leavitt, in the 2008 Nation... brings together leading stakeholders from key sec...
(Date:11/21/2008)...Social Security benefits see more of their limited... Belleville, IL (Vocus) November 21, 2008 -- ...viduals are realizing they will face higher health..., according to Allsup , a leading provider of Soc...related services to people with disabilities. , , ...
(Date:11/21/2008)...w Website is Simple, Powerful and Extremely Intuit...ts Easier than Ever , Mad...y Products is proud to announce that their website...edesigned using state-of-the-art technology. The n...a clean new layout to make shopping for safety pro...
Breaking Medicine News(10 mins):Health News:Miami's Soluna MD Introduces New Cosmetic Surgery Facelift Technique With Permalift 2Health News:Miami's Soluna MD Introduces New Cosmetic Surgery Facelift Technique With Permalift 3Health News:Miami's Soluna MD Introduces New Cosmetic Surgery Facelift Technique With Permalift 4Health News:MediConnect Participates in 2008 National Health Summit 2Health News:Allsup Finds Healthcare Costs Consuming Larger Part of Fixed Incomes 2Health News:Allsup Finds Healthcare Costs Consuming Larger Part of Fixed Incomes 3Health News:Allsup Finds Healthcare Costs Consuming Larger Part of Fixed Incomes 4Health News:Allsup Finds Healthcare Costs Consuming Larger Part of Fixed Incomes 5Health News:Allsup Finds Healthcare Costs Consuming Larger Part of Fixed Incomes 6Health News:Conney Safety Products, Leader in Safety Equipment and Supplies, Launches New Website 2(Date:11/20/2008)...OLLA, Calif., Nov. 20 Du...), announced today that it has submitted its,pivo...iew under a Special,Protocol Assessment (SPA) pro...,(FDA). , Subject to securing an agreement ... prospective, double-blind, placebo-controlled and...
(Date:11/20/2008)...ON, Nov. 20 PAREXEL Inte... global biopharmaceutical services provider, today...eru to provide regulatory consulting and clinical ...ru office, PAREXEL now has locations throughout fi...erica, which also include Argentina, Brazil, Chile...
(Date:11/19/2008)...SAND OAKS, Calif., Nov. 19 /PRNewswire-FirstCall/ ...keda Oncology Company, a subsidiary of,Takeda Pha...ounced that,enrollment in the Phase 3 MONET1 tria...ith paclitaxel and carboplatin for the first-line ...(NSCLC) has been temporarily suspended,following ...
(Date:11/19/2008)...ROCHELLE, N.Y., Nov. 19 Biotech sc...logies to toxicology research to better understand... of organ systems, reports Genetic Engineering &a...ly interested in figuring out a new compound,s mec...ctive toxicology technique, according to the Novem...
Breaking Medicine Technology:Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 2Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 3Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 4PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 3PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7GEN Reports on the Trend Toward Predictive Toxicogenomics 2The University of Nottingham in the British Midlands Announces Development of Possible Hepatitis C Vaccine 616 1The University of Nottingham in the British Midlands Announces Development of Possible Hepatitis C Vaccine 616 2The University of Nottingham in the British Midlands Announces Development of Possible Hepatitis C Vaccine 616 3InterCure and Mashco Announce Launch into Independent Pharmacies in the United Kingdom 612 1InterCure and Mashco Announce Launch into Independent Pharmacies in the United Kingdom 612 2InterCure and Mashco Announce Launch into Independent Pharmacies in the United Kingdom 612 3InterCure and Mashco Announce Launch into Independent Pharmacies in the United Kingdom 612 4Mechanism for the in vivo transport of siRNA 419 1Mechanism for the in vivo transport of siRNA 419 2Mechanism for the in vivo transport of siRNA 419 3Scientists reveal DNA enzyme interaction with first ever real time footage 1361 1Scientists reveal DNA enzyme interaction with first ever real time footage 1361 2...to Be Well Tolerated and Potentially Suited for On..., 2007 /PRNewswire-FirstCall/ --,Pharmacopeia , an...el small molecule therapeutics, today announced po...rial of PS433540, the company,s,lead internal prod...d diabetic nephropathy. Data from the single ascen...
...if., April 11, 2007 /PRNewswire-FirstCall/ --,Phar...ions,regarding its novel histone deacetylase (HDAC... compounds. The presentations,will take place at t... 2007 Annual Meeting being held April 14-18, 2007,...les, CA. , , The presentations are as follows:,...
Other Medicine Technology:Pharmacopeia Announces Positive Results from Initial DARA Clinical,Trial 2Pharmacopeia Announces Positive Results from Initial DARA Clinical,Trial 3Pharmacopeia Announces Positive Results from Initial DARA Clinical,Trial 4Pharmacopeia Announces Positive Results from Initial DARA Clinical,Trial 5Pharmacyclics Announces Presentations on Its Novel and Selective,HDAC and Bruton's Tyrosine Kinase Inhibitor Compounds 2Pharmacyclics Announces Presentations on Its Novel and Selective,HDAC and Bruton's Tyrosine Kinase Inhibitor Compounds 3Pharmacyclics Announces Presentations on Its Novel and Selective,HDAC and Bruton's Tyrosine Kinase Inhibitor Compounds 4Shielding's new Breast Overlay Apron is exclusively designed to provide extra coverage for this vulnerable area. The adjustable velcro flaps allow for a quick, comfortable fit, plust added coverage f
This set includes 2 small, 1 medium, 1 large gonad shields and a belt. The shields and belt is an interchangeable system attached by velcro.
Half aprons used to protect pelvic regions
Collars can be attach to any Pulse aprons.
Medicine Products: